| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The target of MOG (35-55) in research applications is the adaptive immune system, specifically T lymphocytes that recognize this peptide epitope. When administered with adjuvants, the peptide is presented by MHC class II molecules (I-Aᵇ in C57BL/6 mice), leading to activation of MOG-specific CD4+ T cells. These autoreactive T cells then infiltrate the central nervous system (CNS) and initiate an inflammatory response, demyelination, and axonal damage, mimicking human multiple sclerosis.
|
|---|---|
| ln Vitro |
In vitro, MOG (35-55) is used to stimulate T cells isolated from EAE-immunized animals. Splenocytes or lymph node cells from mice immunized with MOG(35-55)/CFA are cultured with 10-50 microg/mL of the peptide for 48-72 hours. T cell proliferation is measured by 3H-thymidine incorporation or CFSE dilution, and cytokine production (e.g., IFN-gamma, IL-17, IL-10) is measured by ELISA or flow cytometry. The peptide also induces production of anti-MOG autoantibodies in B cells.
|
| ln Vivo |
The human MOG (35-55) peptide induces minimal clinical signs of experimental autoimmune encephalomyelitis (EAE) relative to the rodent MOG(35-55) peptide, which has a different residue at position 42 (Serine in mouse/rat vs. Proline in human). The human peptide is still immunogenic but less potent. In vivo, when emulsified in complete Freund's adjuvant (CFA) and administered with pertussis toxin, it induces an autoantibody response that serves as a model of experimental autoimmune encephalomyelitis and multiple sclerosis. It can be used to induce EAE in mouse and rat models for human multiple sclerosis research.
|
| Enzyme Assay |
A standard cell-free assay for this peptide is not applicable, as it is an antigen that requires processing and presentation by antigen-presenting cells. However, the peptide can be used in MHC-peptide binding assays. Recombinant MHC class II molecules (e.g., I-Aᵇ) are immobilized on a plate, and a labeled reference peptide (e.g., a known antigen) is mixed with unlabeled MOG(35-55). The amount of labeled peptide bound is measured, and the IC50 for competition is calculated to determine the binding affinity of MOG(35-55) for MHC.
|
| Cell Assay |
A cellular assay for MOG(35-55) peptide is the ex vivo T cell recall response. Mice are immunized with MOG(35-55) peptide emulsified in CFA. After 10-14 days, splenocytes or lymph node cells are isolated and cultured with varying concentrations of MOG(35-55) (e.g., 0.1-50 microg/mL) for 48-72 hours. Cell proliferation is measured by 3H-thymidine incorporation or by using a colorimetric assay (e.g., BrdU ELISA). Cytokine levels in the culture supernatant are measured by ELISA or a bead-based multiplex assay. Flow cytometry is used to assess T cell activation markers (e.g., CD25, CD44) and T helper subset polarization.
|
| Animal Protocol |
The in vivo induction of EAE is the primary animal model for MOG(35-55) peptide. C57BL/6 mice (7-10 weeks old) are immunized subcutaneously with 100-200 microg of MOG(35-55) peptide emulsified 1:1 in CFA containing 4 mg/mL heat-killed Mycobacterium tuberculosis H37Ra (200 microL total volume, divided over two flanks). Additionally, 200 ng pertussis toxin (PTX) in 200 microL PBS is administered intraperitoneally on days 0 and 2 post-immunization. Animals are scored daily for clinical signs of EAE on a scale of 0-5 (0: no signs; 1: flaccid tail; 2: hind limb weakness or partial paralysis; 3: complete hind limb paralysis; 4: forelimb weakness; 5: moribund). At the end of the study, spinal cords are collected for histopathological analysis (Luxol Fast Blue for demyelination, H&E for inflammation).
|
| ADME/Pharmacokinetics |
The human MOG (35-55) peptide is a synthetic peptide with a molecular weight of approximately 2590-2592 Daltons. It is typically supplied as a lyophilized powder or a TFA salt. For reconstitution, it is dissolved in sterile water or PBS to a stock concentration of 1-5 mg/mL. Once reconstituted, it should be aliquoted and stored at -20degC or -80degC to avoid freeze-thaw cycles. It is stable as a powder at -20degC for several years. For immunization, it is emulsified 1:1 in CFA, which must be prepared fresh and administered immediately.
|
| Toxicity/Toxicokinetics |
MOG (35-55) peptide is not a drug for human use; it is a research tool used to induce an autoimmune reaction in animals. Therefore, its toxicity is evaluated in the context of the EAE model itself, which is an experimental disease state. In mice, the immunization protocol is generally well-tolerated, but animals will develop clinical signs of EAE, which include weight loss, partial or complete paralysis, and in severe cases, euthanasia is required. The severity of the disease is an experimental endpoint, not an adverse toxicological effect. Standard safety precautions for handling synthetic peptides should be followed.
|
| References |
[1]. Cathleen Rich, et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004 May;34(5):1251-61.
[2]. Alfred R Oliver, et al.Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol. 2003 Jul 1;171(1):462-8. |
| Additional Infomation |
The human MOG (35-55) peptide (CAS 163158-19-8) is a synthetic peptide derived from the myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. It is less encephalitogenic than the rodent MOG(35-55) peptide due to a Pro⁴2 to Serine substitution, which is not present in mice. The human sequence has applications in structural immunology and peptide biophysics to understand epitope structure and backbone dynamics, and it can be used to generate humanized models of MS. The peptide is for research and industrial applications only and is not intended for clinical or medical use.
|
| Molecular Formula |
C120H179N35O28S
|
|---|---|
| Molecular Weight |
2591.99
|
| Exact Mass |
2590.34
|
| CAS # |
163158-19-8
|
| PubChem CID |
155886032
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.202
|
| Hydrogen Bond Donor Count |
37
|
| Hydrogen Bond Acceptor Count |
35
|
| Rotatable Bond Count |
82
|
| Heavy Atom Count |
184
|
| Complexity |
5750
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C)CC[C@@H](C(N[C@@H](CCC(=O)O)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCCNC(=N)N)C(N1CCC[C@H]1C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(=O)O)CCCCN)=O)=O)CC(N)=O)=O)CCCNC(=N)N)=O)CC1=CC=C(C=C1)O)=O)CC(C)C)=O)CC1=CNC=N1)=O)C(C)C)=O)C(C)C)=O)CCCNC(=N)N)=O)CO)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)N
|
| InChi Key |
JZTWEKCSWFQBIT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C120H179N35O28S/c1-63(2)50-82(104(169)145-83(52-68-32-36-72(157)37-33-68)105(170)141-77(27-17-44-131-118(124)125)101(166)147-88(56-92(123)159)100(165)135-59-93(160)138-81(117(182)183)26-15-16-43-121)144-109(174)87(55-71-58-130-62-137-71)149-113(178)97(65(5)6)153-114(179)98(66(7)8)152-102(167)78(28-18-45-132-119(126)127)142-110(175)89(61-156)150-107(172)85(51-67-22-11-10-12-23-67)148-111(176)90-30-20-47-154(90)116(181)91-31-21-48-155(91)115(180)80(29-19-46-133-120(128)129)143-106(171)84(53-69-34-38-73(158)39-35-69)146-108(173)86(54-70-57-134-76-25-14-13-24-74(70)76)139-94(161)60-136-112(177)96(64(3)4)151-103(168)79(40-41-95(162)163)140-99(164)75(122)42-49-184-9/h10-14,22-25,32-39,57-58,62-66,75,77-91,96-98,134,156-158H,15-21,26-31,40-56,59-61,121-122H2,1-9H3,(H2,123,159)(H,130,137)(H,135,165)(H,136,177)(H,138,160)(H,139,161)(H,140,164)(H,141,170)(H,142,175)(H,143,171)(H,144,174)(H,145,169)(H,146,173)(H,147,166)(H,148,176)(H,149,178)(H,150,172)(H,151,168)(H,152,167)(H,153,179)(H,162,163)(H,182,183)(H4,124,125,131)(H4,126,127,132)(H4,128,129,133)
|
| Chemical Name |
6-amino-2-[[2-[[4-amino-2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[1-[1-[2-[[2-[[2-[[2-[[2-[[2-[(2-amino-4-methylsulfanylbutanoyl)amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3858 mL | 1.9290 mL | 3.8580 mL | |
| 5 mM | 0.0772 mL | 0.3858 mL | 0.7716 mL | |
| 10 mM | 0.0386 mL | 0.1929 mL | 0.3858 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
